Center News

GI oncologist Coveler joins Center

Andrew Coveler adds cancer immunotherapy, translational research expertise to Clinical Research Division

April 9, 2012
Dr. Andrew Coveler

Dr. Andrew Coveler's research encompasses early phase clinical trials of new cancer drugs and immune-based treatments like vaccines and antibodies.

Photo by Dean Forbes

Dr. Andrew Coveler has joined the Hutchinson Center's Clinical Research Division faculty. His research encompasses early phase clinical trials of new cancer drugs and immune-based treatments like vaccines and antibodies.

Coveler's primary appointment is at the University of Washington, where he is an assistant professor of gastrointestinal oncology.
 
Former Center hematology-oncology fellow

Coveler has been an attending physician at Seattle Cancer Care Alliance and a member of UW's Tumor Vaccine Group since 2010. Previously, he completed a hematology-oncology fellowship at the Center and worked at Swedish Medical Center. He received his medical degree from Northwestern University's Feinberg School of Medicine.

Coveler, who joined the Center late last year, said he is excited to join a research team at the forefront of immunological approaches to fighting cancer. "I believe the immune system has great power to help patients with cancer live longer, and the Center is the leading location for immune-based treatments of cancer," he said.

"Andrew has a passion for patient care and teaching and is developing a vibrant clinical translational research program based on cancer immunotherapy," said Dr. Mac Cheever, director of the Center's Solid Tumor Research Program. "He organized and led the first Fred Hutchinson/University of Washington Comprehensive Oncology Review Course. Due largely to his efforts, the course is evolving to become a major outreach teaching endeavor for the UW Medicine Oncology Program."

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.